Method of treatment
OwnerShahnaz Shahinfar, Zhongxin Zhang +1inventors
InventorsShahnaz Shahinfar, Zhongxin Zhang, Barry M. Brenner
Life of this patent
Estimating the term…
Abstract
This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[(2′-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2′-(tetrazol-5-yl)-1,1′-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine, or pharmaceutically acceptable salts thereof are useful.
Claims32
A method of preventing end stage renal failure in patients with impaired renal function comprising administration of a therapeutically effective amount of an angiotensin II antagonist or a composition containing an angiotensin II antagonist.
A method of delaying the progression of renal disease in patients with impaired renal function comprising administration of a therapeutically effective amount of an angiotensin II antagonist or a composition containing an angiotensin II antagonist.
A method of slowing the development of end stage renal disease in patients with nephropathy comprising administration of a therapeutically effective amount of an angiotensin II antagonist or a composition containing an angiotensin II antagonist.
A method of reducing hospitalization for heart failure in patients without clinical signs of heart failure, and who have impaired renal function comprising administration of a therapeutically effective amount of an angiotensin II antagonist or a composition containing an angiotensin II antagonist.
Dependencies are inferred from the claim text.